Home Analysis of patients with γ-heavy chain disease by the heavy/light chain and free light chain assays
Article
Licensed
Unlicensed Requires Authentication

Analysis of patients with γ-heavy chain disease by the heavy/light chain and free light chain assays

  • Erin Kaleta , Robert Kyle , Raynell Clark and Jerry Katzmann EMAIL logo
Published/Copyright: December 11, 2013

Abstract

Background: The objective of this study was to evaluate the performance of the heavy/light chain and free light chain immunoassays in patients with heavy chain disease, and to assess the ability of the heavy/light chain assay to measure and confirm the abnormal, truncated heavy chain.

Methods: Frozen serum samples from 15 γ-heavy chain disease patients were tested for IgGκ, IgGλ, total IgG, free light chains, and M-spike concentrations.

Results: The (Gκ+Gλ)/IgGtotal ratio for these 15 patients ranged from 0.02 to 0.80. The 10 patients with IgG concentrations above 1 g/dL all had ratios below 0.3 indicating that a substantial portion of IgG was not quantitated by the Gκ and Gλ reagents. The average M-spike was 1.61 g/dL and the average calculated abnormal γ-chain concentration was 2.94 g/dL. Additionally, free light chain analysis revealed the presence of monoclonal free κ light chain in three of the 15 patients.

Conclusions: This study demonstrates utility of a nephelometric assay to identify truncated immunoglobulin heavy chains in γ-HCD and that 20% of these patients also have monoclonal free light chain.


Corresponding author: Jerry Katzmann, PhD, Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic Hilton 210, 200 1st St SW, Rochester, MN 55905, USA, Fax: +1 507 2664088, E-mail: .

References

1. Wahner-Roedler DL, Kyle RA. Heavy chain diseases. Best Pract Res Clin Haematol 2005;18:729–46.10.1016/j.beha.2005.01.029Search in Google Scholar

2. Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore) 2003;82:236–50.10.1097/01.md.0000085058.63483.7fSearch in Google Scholar

3. Bieliauskas S, Tubbs RR, Bacon CM, Eshoa C, Foucar K, Gibson SE, et al. Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases. Am J Surg Pathol 2012;36:534–43.10.1097/PAS.0b013e318240590aSearch in Google Scholar

4. Kyle RA, Greipp PR, Banks PM. The diverse picture of gamma heavy-chain disease. Report of seven cases and review of literature. Mayo Clin Proc 1981;56:439–51.Search in Google Scholar

5. Franklin EC, Lowenstein J, Bigelow B, Meltzer M. Heavy chain disease – a new disorder of serum gamma-globulins: report of the first case. Am J Med 1964;37:332–50.10.1016/0002-9343(64)90191-3Search in Google Scholar

6. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517–22.10.1373/clinchem.2009.126664Search in Google Scholar PubMed PubMed Central

7. Lee MT, Parwani A, Humphrey R, Hamilton RG, Myers DI, Detrick B. Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment. J Clin Lab Anal 2008;22:146–50.10.1002/jcla.20233Search in Google Scholar PubMed PubMed Central

8. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009;55:1646–55.10.1373/clinchem.2009.123828Search in Google Scholar PubMed

9. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009;55:1523–9.10.1373/clinchem.2009.124461Search in Google Scholar PubMed

10. Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.10.1046/j.1365-2141.2003.04355.xSearch in Google Scholar

11. Durie BG, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.10.1038/sj.leu.2404284Search in Google Scholar PubMed

Received: 2013-8-30
Accepted: 2013-11-14
Published Online: 2013-12-11
Published in Print: 2014-5-1

©2014 by Walter de Gruyter Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Potential application of fetal epigenetic markers on the non-invasive prenatal detection of chromosomal abnormality
  4. Review
  5. Epigenetic mechanisms in bone
  6. Opinion Papers
  7. Circulating fetal cell-free DNA and prenatal molecular diagnostics: are we ready for consensus?
  8. Hepcidin levels in chronic hemodialysis patients: a critical evaluation
  9. D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL
  10. General Clinical Chemistry and Laboratory Medicine
  11. Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma
  12. Non-invasive detection of fetal trisomy 21 using fetal epigenetic biomarkers with a high CpG density
  13. Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid
  14. Instability of cerebrospinal fluid after delayed storage and repeated freezing: a holistic study by drop coating deposition Raman spectroscopy
  15. Analysis of patients with γ-heavy chain disease by the heavy/light chain and free light chain assays
  16. Performance of urinary NGAL and L-FABP in predicting acute kidney injury and subsequent renal recovery: a cohort study based on major surgeries
  17. Rapid extraction, identification and quantification of drugs of abuse in hair by immunoassay and ultra-performance liquid chromatography tandem mass spectrometry
  18. Validity and reliability of the 13C-methionine breath test for the detection of moderate hyperhomocysteinemia in Mexican adults
  19. Quantitative detection of target cells using unghosted cells (UGCs) of DxH 800 (Beckman Coulter)
  20. Evaluation of different sized blood sampling tubes for thromboelastometry, platelet function, and platelet count
  21. Cancer Diagnostics
  22. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations
  23. Analytical performance of a new one-step quantitative prostate-specific antigen assay, the FREND™ PSA Plus
  24. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis
  25. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival
  26. Cardiovascular Diseases
  27. Red blood cell distribution width predicts survival in patients with Eisenmenger syndrome
  28. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients
  29. Corrigendum
  30. Standardization and analytical goals for glycated hemoglobin measurement
  31. Letter to the Editors
  32. Do we need to worry about contamination by circulating fetal DNA?
  33. Stat testing utilization in clinical laboratories. National survey of Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC)
  34. Aldosterone measurement with LiaisonXL automated system: remarks about reference range
  35. Better blood collection tubes for plasma glucose: ready for prime time?
  36. Upregulation of cytokines and IL-17 in patients with hereditary angioedema
  37. Underestimation of platelet count on magnesium salt-anticoagulated samples
  38. Extensive elevation of BNP but not NT-ProBNP in a patient with advanced urothelial carcinoma in absence of cardiac failure and volume overload
Downloaded on 19.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0714/html
Scroll to top button